The SPARE score reliably predicts the conversion from open partial to radical nephrectomy

**Aim** To assess the power of nephrometry scores to predict the intraoperative conversion from partial nephrectomy (PN) to radical nephrectomy (RN).

**Methods** We identified all the patients at our institution who were scheduled for PN between April 2012 and December 2017. Patients who underwent robotic or laparoscopic surgery were excluded. A total of 149 patients (94 men) who underwent open surgery and had complete data were included. The power of the R.E.N.A.L., PADUA, SPARE, and DAP scores to predict the conversion to RN, and the threshold values were assessed. In the multivariate analysis, the predictive power of the nephrometry scores was tested by separately including them in different models.

**Results** The median age was 57 (48-67) years, while the median follow-up was 15 (7-29.5) months. The overall conversion rate was 10.7%. The optimal cut-off values for the R.E.N.A.L., PADUA, SPARE, and DAP scores were 7.5, 9.5, 5.5 and 7.5, respectively. The SPARE score had the highest area under the curve (AUC = 0.807, \( P < 0.001 \)). In the multivariate analysis, the SPARE score had the highest odds ratio (OR 12.561; confidence interval 3.456-45.534, \( P < 0.001 \)).

**Conclusion** A high SPARE score was significantly associated with the conversion to RN in patients who underwent open PN.
Renal cell carcinoma (RCC) constitutes 2%-3% of adult cancers (1). Although many patients with RCC remain asymptomatic until the late disease stages, the majority are diagnosed at a localized stage (1,2), when surgery is a highly effective curative treatment (1). Surgical treatment options include partial and radical nephrectomy (RN) (1). Partial nephrectomy (PN) is the standard treatment method for patients with T1a tumors, while providing similar results in patients with T1b and T2 tumors (3).

As PN preserves the kidney functions, it decreases the risk of chronic kidney disease (CKD) and subsequent cardiovascular disease risk (4,5). However, PN is a complex surgical procedure with high complication rates compared with RN (6). In recent years, PN has been applied for treatment of complex renal tumors, which carries an increased risk of the conversion to RN (7,8).

Various nephrometry scores have been developed to standardize the reporting of renal mass size in patients scheduled for RCC surgery (9-12). To the best of our knowledge, no study so far has compared the four nephrometry scores in terms of conversion to RN prediction. In this study, we retrospectively tested the power of nephrometry scores to predict the intraoperative conversion from PN to RN in patients with RCC.

PATIENTS AND METHODS

We retrospectively reviewed the records of 274 consecutive patients who underwent PN due to a solitary renal tumor between April 2012 and December 2017. Patients without preoperative cross-sectional imaging recorded in the hospital information system (n=82) or those who underwent robotic or laparoscopic surgery (n=43) were excluded (Figure 1). The data of 149 patients who underwent open PN and had complete data were analyzed. The study was approved by the Ethics Committee of Hacettepe University.

All patients underwent preoperative cross-sectional imaging (abdominal computed tomography [CT] or magnetic resonance imaging [MRI]), and thorax CT to evaluate the presence of lung metastasis at the time of diagnosis. The patients scheduled for PN who subsequently underwent RN were identified. The nephrometry scores were calculated by the same urologist (H.B.H.).

Hemoglobin levels below 12 g/dL for women and below 13 g/dL for men indicated anemia (13). Renal function was assessed with the estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease equation (MDRD) (14). CKD was defined as eGFR<60 mL/min/1.73m². Charlson Comorbidity Index (CCI) was used to determine the patients’ general health in the preoperative period (15). Complications that occurred within 30 days after surgery were evaluated according to the Clavien-Dindo complication classification system (16); patients were classified into two groups: minor (Clavien-Dindo 1-2) and major (Clavien-Dindo 3-4) complications group. Blood transfusions were performed intraoperatively due to excessive bleeding or a hemoglobin drop, or postoperatively due to vital signs changes. Tumor complexity was assessed by using the R.E.N.A.L. (maximum tumor diameter, exophyt-
ic/endophytic properties, proximity to the collecting system or sinus, and location relative to the polar line), PADUA (longitudinal tumor location, rim location, relationships with the sinus, relationships with the urinary collecting system, percentage of the tumor protruding into the kidney, and maximum tumor diameter), SPARE (rim location, relationships with the sinus, percentage of the tumor protruding into the kidney, and maximum tumor diameter), and DAP (maximum tumor diameter, axial distance, and polar distance) scores (9-12). The R.E.N.A.L. score was considered low if 4–6, intermediate if 7–9, and high if 10–12. The PADUA score was classified as low if 6–7, intermediate if 8–9, and high if ≥10. The SPARE score was classified as low if 0–3, intermediate if 4–7, and high if 8–10. DAP score was classified as low if 3–5 and high if 6–9.

We gathered data on patient demographics and perioperative variables, including age, sex, body mass index, CCI, preoperative CKD, preoperative anemia, hospitalization time, and drain removal time. Tumor size, tumor location, and the R.E.N.A.L., PADUA, SPARE, and DAP scores were obtained by a review of preoperative imaging. Surgical data included estimated blood loss (EBL), intraoperative complications, operative time, and intraoperative transfusion rates. Pathological data included pathological tumor size, histology, nuclear grade, and pathological stage.

PN was performed using an open transperitoneal technique. Depending on the tumor properties, wedge resection or enucleation was performed. Warm hilar ischemia or ultrasound were performed at the primary surgeon’s discretion.

The patients were classified into two groups according to the conversion from PN to RN (conversion or no conversion). The two groups were compared in terms of patient demographics and tumor characteristics. The factors affecting the conversion to RN were evaluated in models that included each of the nephrometry scores individually.

### Statistical analysis

The normality of distribution was assessed with the Kolmogorov-Smirnov test. Parametric variables are presented as mean ± standard deviation, while nonparametric variables are presented as median and interquartile range. In the univariate analysis, the χ² test or Fisher exact test were used for the comparison of nominal data, the t test for parametric variables, and the Mann-Whitney U test for nonparametric variables. Receiver operating characteristic (ROC) curves were plotted to assess the predictive value of the R.E.N.A.L., PADUA, SPARE, and DAP scores for conversion to RN. The threshold values were determined using the ROC curves, and the value with the highest sensitivity and specificity was calculated. Binary logistic regression analysis and backward stepwise model were used in the multivariate analysis. The significance level was set at P < 0.05. The statistical analyses were performed with the SPSS for Windows, version 24.0 (IBM Corp., Armonk, NY, USA).

### RESULTS

The median age was 57 (range 48-67) years. The median follow-up was 15 (range 7-29.5) months. Patients’ demographic and preoperative characteristics are shown in Table 1. Of 149 patients who underwent PN, 16 (10.7%) experienced the conversion to RN. The reasons for the conversion were tumor size discordance (the tumor was larger than expected) or suspicion of advanced disease (n = 6, 37.5%), invasion of hilar structures (n = 5, 31.25%), insufficient renal remnant after resection (n = 1, 6.25%), compromised renal arterial supply after resection (n = 1, 6.25%), failure to progress in surgery (n = 1, 6.25%), and failure to achieve clear margins (n = 1, 6.25%). One patient was hospitalized for retroperitoneal bleeding on postoperative day 12, and completion nephrectomy was performed.

High R.E.N.A.L., PADUA, SPARE, and DAP scores were associated with the conversion to RN. In ROC analysis, the SPARE score had the highest area under curve (AUC = 0.807) (Figure 2, Table 2).

In the univariate analysis, tumor size, clinical tumor stage, the R.E.N.A.L., PADUA, SPARE, and DAP score were associated with the conversion to RN (P < 0.001, P = 0.001, P < 0.001, P < 0.001, P < 0.001, P = 0.004, respectively). When evaluated individually in separate models in the multivariate analysis, the R.E.N.A.L., PADUA, SPARE and DAP scores were significantly associated with RN conversion (P = 0.009, P = 0.001, P < 0.001, P = 0.003, respectively). The SPARE score had the highest odds ratio (OR 12.561; confidence interval 3.456-45.534) (Table 3).

The number of patients with Clavien-Dindo grade 1, grade 2, grade 3a, and grade 4a was 4 (2.7%), 7 (4.7%), 3 (2%), and 2 (1.3%), respectively. Six patients (4%) required intraoperative and 6 patients (4%) required postoperative blood transfusion. Perioperative outcomes are shown in Table 4.
Histopathological examination revealed malignant pathology in 114 (76.5%) patients, the majority of whom had clear cell RCC (n = 72, 48.3%). Pathological, oncological, and functional outcomes are shown in Table 4.

In the follow-up period, 2 patients had local recurrence, while 2 patients developed distant metastases. Local recurrences were observed 15 and 24 months after PN. Among patients with local recurrences, one patient underwent TABLE 1. Clinical and preoperative characteristics*  

| Parameters                                      | Entire cohort | Conversion | No conversion | P      |
|-------------------------------------------------|---------------|------------|---------------|--------|
| N, %                                            | 149 (100)     | 16 (10.7)  | 133 (89.3)    | -      |
| Age in years; median (IQR)                      | 57 (48-67)    | 59 (51.25-67) | 57 (47.5-66.5) | 0.602* |
| BMI (kg/m²); median (IQR)                       | 27.06 (24.34-31.22) | 25.31 (23.33-28) | 27.17 (24.35-32.48) | 0.148* |
| Charlson comorbidity index; median (IQR)        | 2 (1-3)       | 2 (1-3)    | 2 (1-3)       | 0.841† |
| Preoperative eGFR (mL/min/1.73m²); mean ± standard deviation | 96.1 (27) | 95.3 (29.4) | 96.1 (26.8) | 0.909* |
| Preoperative creatinine, (mg/dL); median (IQR)  | 0.8 (0.67-1.01) | 0.89 (0.75-1.07) | 0.80 (0.67-1.01) | 0.306† |
| Preoperative chronic kidney disease; No. (%)    | 15 (10.1)     | 1 (6.3)    | 14 (10.5)     | 0.591† |
| Preoperative anemia; No. (%)                    | 29 (19.5)     | 4 (25)     | 25 (18.8)     | 0.516† |
| Preoperative diabetes mellitus; No. (%)         | 27 (18.1)     | 3 (18.8)   | 24 (18)       | 0.945§  |
| Preoperative hypertension; No. (%)              | 59 (39.6)     | 6 (37.5)   | 53 (39.8)     | 0.856§  |
| Female sex; No. (%)                             | 55 (36.9)     | 3 (18.7)   | 52 (39.1)     | 0.111§  |
| Symptomatic presentation; No. (%)               | 47 (31.5)     | 7 (43.7)   | 40 (30.1)     | 0.266§  |
| Tumor size (cm); median (IQR)                   | 3.38 (2.49-4.81) | 4.91 (3.91-5.89) | 3.29 (2.42-4.12) | <0.001* |
| Left tumor side; No. (%)                        | 74 (49.7)     | 9 (56.3)   | 65 (48.9)     | 0.577§  |
| Clinical tumor stage; No. (%)                   |               |            |               |        |
| T1a                                             | 92 (61.7)     | 3 (18.8)   | 89 (66.9)     | 0.001* |
| T1b                                             | 46 (30.9)     | 10 (62.4)  | 36 (27.1)     |        |
| T2                                              | 11 (7.4)      | 3 (18.8)   | 8 (6)         |        |
| R.E.N.A.L. score; No. (%)                       |               |            |               |        |
| low                                             | 82 (55)       | 2 (12.4)   | 80 (60.2)     | <0.001*|
| intermediate                                    | 55 (36.9)     | 7 (43.8)   | 48 (36.1)     |        |
| high                                            | 12 (8.1)      | 7 (43.8)   | 5 (3.7)       |        |
| P.A.D.U.A. score; No. (%)                       |               |            |               |        |
| low                                             | 55 (36.9)     | 0 (0)      | 55 (41.4)     | <0.001*|
| intermediate                                    | 55 (36.9)     | 4 (25)     | 51 (38.3)     |        |
| high                                            | 39 (26.2)     | 12 (75)    | 27 (20.3)     |        |
| S.P.A.R.E. score; No. (%)                       |               |            |               |        |
| low                                             | 95 (63.8)     | 2 (12.5)   | 93 (69.9)     | <0.001*|
| intermediate                                    | 49 (32.8)     | 11 (68.7)  | 38 (28.6)     |        |
| high                                            | 5 (3.4)       | 3 (18.8)   | 2 (1.5)       |        |
| D.A.P. score; No. (%)                           |               |            |               |        |
| low                                             | 59 (39.6)     | 1 (6.3)    | 58 (43.6)     | 0.004*  |
| high                                            | 90 (60.4)     | 15 (93.7)  | 75 (56.4)     |        |

*Abbreviations: IQR – Interquartile range; BMI – body mass index; eGFR – estimated glomerular filtration rate.
†Mann-Whitney U test.
‡t-test.
§χ² test.

TABLE 2. Sensitivity, specificity, and threshold values of nephrometry scores in receiver operating characteristic (ROC) curve analysis
surgical treatment and another patient was prescribed tyrosine kinase inhibitors after surgical treatment of recurrence. Tyrosine kinase inhibitors were initiated in patients with metastatic disease.

DISCUSSION

In the present study, a high SPARE score was significantly associated with the conversion to RN in patients who underwent open PN.

The rates of conversion to RN vary widely according to surgeon’s experience, center’s experience, and the procedure type (17-21). The conversion to RN rate in this open PN study was slightly higher than those reported in other open PN series (18,19). Over the years, the PN application has expanded to patients with more complex renal masses. The literature reports that PN can be applied in patients with T1b and T2 tumors (3,22,23). T1b and T2 tumor rates in the present study were higher compared with those in a multi-institutional study by Arora et al (20). This difference might have affected the high conversion rate observed in the current study. Our hospital being a urooncology referral center may explain the observed high tumor size, T1b and T2 tumors rates, and the conversion to RN rate.

The conversion to RN can be caused by various factors, especially oncological concerns. In the present study, the main reasons for the conversion were hilar invasion, suspected advanced disease, and tumor size discordance. Positive surgical margins after PN are reported to be significantly associated with worse overall survival (24). In agreement with oncological principles, pT3 rate was significantly higher in the converted group.

Among the nephrometry scores analyzed in the present study, the SPARE had the highest AUC in ROC analysis and the highest OR for the conversion to RN. The SPARE score was developed by Ficarra et al by simplifying the PADUA score (12) with an aim to predict postoperative complications. We, on the other hand, used the SPARE score to predict the conversion to RN, which is an intraoperative complication. The main advantage of the SPARE score over...
other nephrometry scores for the prediction of the conversion to RN is the inclusion of more factors that can separately lead to the conversion to RN. Therefore, we believe that the SPARE score might be useful in the preoperative evaluation of the conversion to RN.

In line with previously published studies (17-19), in our study tumor size was a significant predictor of the conversion to RN in the univariate analysis, but in the multivariate analysis this effect disappeared. Notably, the rate of the conversion to RN is expected to increase with the increasing tumor size.

Unlike in other studies, preoperative kidney function in our study was not predictive for the conversion to RN (17,18). This difference may be explained by performing PN to protect the existing kidney function and by tumors not suitable for PN in patients with poor basal kidney function. In our study, 14 patients with preoperative CKD underwent successful PN, and of these patients, 3 had cT2a disease. Therefore, PN should be performed in all patients with a tumor suitable for PN regardless of preoperative kidney function.

The study limitations include the retrospective design, relatively small sample size, and single-center setting. Since all surgeons in our study had a high level of experience in urooncology (≥200 procedures), surgical experience was not included as a parameter. Another limitation is that nephrometry scores were calculated only by a single urologist. However, it was shown that physicians without specialized radiological training are equally successful in the calculation of nephrometry scores as board certified radiologists (25,26). The inclusion of patients who were operated on with open surgical technique can be considered as a limitation as well. However, European Association of Urology guidelines state that PN can be performed with open, laparoscopic, or robotic approaches, with the treatment choice being based on surgeon’s expertise and skills (27). Besides, laparoscopic and robotic PN have been shown to have a longer learning curve than open PN (28). Given our center’s great experience in performing open PN and the fact that all surgeons in our center did not complete the learning curve for minimally invasive procedures, only patients who underwent open surgery were evaluated. Despite these limitations, we believe that the results of our study add to the current literature, as to the best of our knowledge, this is the first study comparing four different nephrometry scores and showing that SPARE score can also be used in predicting the conversion to RN.

In conclusion, we showed that a high SPARE score (>5.5) was an independent prognostic factor for pre-
dicting the conversion to RN in patients undergoing open PN. This nephrometry score may be used to inform the patients preoperatively about the risk of the conversion to RN during the surgical procedure. Additional studies are needed to corroborate our findings.

Funding None.

Ethical approval Given by the Ethics Committee of Hacettepe University (GO 17/735-19).

Declaration of authorship HBH and AE conceived and designed the study; HBH, BC, and MA acquired the data; HBH, SY, BA, and HO analyzed and interpreted the data; HBH, BC, and MA drafted the manuscript; SY, BA, HO, and AE critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913-24. Medline:25616710 doi:10.1016/j.euro.2015.01.005

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30. Medline:31912902 doi:10.3322/caac.21590

3. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mohtie A, Auturino R. Partial Nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2017;71:606-17. Medline:27614693 doi:10.1016/j.euro.2016.08.060

4. Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2017;12:1057-69. Medline:28483780 doi:10.2215/CJN.11941116

5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305. Medline:15385656 doi:10.1056/NEJMoa041031

6. Berg WT, Tomaszewski JJ, Yang H, Corcoran A. Complications of renal surgery. Urol Clin North Am. 2017;44:275-88. Medline:28411919 doi:10.1016/j.ucl.2016.12.013

7. Wang Y, Shao J, Ma X, Du Q, Gong H, Zhang X. Robotic and open partial nephrectomy for complex renal tumors: a matched-pair comparison with a long-term follow-up. World J Urol. 2017;35:73-80. Medline:27194142 doi:10.1007/s00345-016-1849-8

8. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, et al. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. Urology. 2012;80:347-53. Medline:22698478 doi:10.1016/j.urology.2012.04.043

9. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844-53. Medline:19616235 doi:10.1016/j.juro.2009.05.035

10. Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009;56:766-93. Medline:19665284 doi:10.1016/j.euro.2009.07.040

11. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Diameter-axial-polar nephrometry: integration and optimization of R.E.N.A.L. and centrality index scoring systems. J Urol. 2012;188:384-90. Medline:2269624 doi:10.1016/j.juro.2012.03.123

12. Ficarra V, Porpiglia F, Crestani A, Minervini A, Antonelli A, Longo N, et al. The Simplified PADUA Renal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy. BJU Int. 2019. Ahead of Print.

13. Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: does hemoglobin change with aging? Semin Hematol. 2015;52:261-9. Medline:26404438 doi:10.1053/j.seminhematol.2015.07.006

14. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004;44:84-93. Medline:15211142 doi:10.1053/j.ajkd.2004.03.027

15. Carlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83. Medline:3558716 doi:10.1016/0021-9681(87)90171-8

16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;239:225-32. Medline:15273542 doi:10.1097/01.sla.0000133083.54934.ae

17. Kara O, Maurice MJ, Mouracade P, Malkoc E, Dagenais J, Nelson RJ, et al. When partial nephrectomy is unsuccessful: understanding the reasons for conversion from robotic partial to radical nephrectomy at a tertiary referral center. J Urol. 2017;198:30-5. Medline:28087299 doi:10.1016/j.juro.2017.01.019

18. Galvin DJ, Savage CJ, Adamy A, Kaag M, O’Brien MF, Kallingal G, et al. Intraoperative conversion from partial to radical nephrectomy at a single institution from 2003 to 2008. J Urol. 2011;185:1204-9. Medline:21334022 doi:10.1016/j.juro.2010.11.077

19. Petrofs FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, et al. Intraoperative conversion from partial to radical nephrectomy: incidence, predictive factors, and outcomes. Urology. 2018;116:114-9. Medline:29578041 doi:10.1016/j.urology.2018.03.017

20. Arora S, Chun B, Ahlawat RK, Abaza R, Adshead J, Porter JR,
et al. Conversion of robot-assisted partial nephrectomy to radical nephrectomy: a prospective multi-institutional study. Urology. 2018;113:85-90. Medline:29284123 doi:10.1016/j.urology.2017.11.046

21 Khandwala YS, Jeong IG, Kim JH, Han DH, Li S, Wang Y, et al. The incidence of unsuccessful partial nephrectomy within the United States: A nationwide population-based analysis from 2003 to 2015. Urol Oncol. 2017;35(12):e72-13.

22 Fero K, Hamilton ZA, Bindayi A, Murphy JD, Derweesh IH. Utilization and quality outcomes of cT1a, cT1b and cT2a partial nephrectomy: analysis of the national cancer database. BJU Int. 2018;121:565-74. Medline:29032581 doi:10.1111/bju.14055

23 Ristau BT, Handorf EA, Cahn DB, Kutikov A, Uzzo RG, Smaldone MC. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer database. Cancer. 2018;124:3839-48. Medline:30207380 doi:10.1002/cncr.31582

24 Shum CF, Bahler CD, Sundaram CP. Impact of positive surgical margins on overall survival after partial nephrectomy-A matched comparison based on the National Cancer Database. Urol Oncol. 2018;36(3):90 e15-90 e21.

25 Dahlkamp L, Haeuser L, Winnekendonk G, von Bodman C, Frey UH, Epplen R, et al. Interdisciplinary comparison of PADUA and R.E.N.A.L. Scoring systems for prediction of conversion to nephrectomy in patients with renal mass scheduled for nephron sparing surgery. J Urol. 2019;202:890-8. Medline:31145034 doi:10.1097/JU.0000000000000361

26 Sharma AP, Mavuduru RS, Bora GS, Devana SK, Palani K, Lal A, et al. Comparison of RENAL, PADUA, and C-index scoring systems in predicting perioperative outcomes after nephron sparing surgery. Indian J Urol. 2018;34:51-5. Medline:29343913 doi:10.4103/iju.IJu_247_17

27 Ljungberg B, Alligies L, Bensalah K, Bex A, Giles RH, Hora M, et al. EAU guidelines on renal cell carcinoma. Edn. presented at the EAU Annual Congress Amsterdam, 2020.

28 Laviana AA, Hu JC. Current controversies and challenges in robotic-assisted, laparoscopic, and open partial nephrectomies. World J Urol. 2014;32:591-6. Medline:24703070 doi:10.1007/s00345-014-1277-6